Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The investigators aim to perform the first controlled randomized prospective study using ECZ
in pediatric STEC-HUS. This is of great interest as there is still no efficient specific
therapy in that potentially devastating disease.
Furthermore, published data concerning the use of ECZ in STEC-HUS are controversial,
reflecting statistical bias in retrospective or uncontrolled studies, thus emphasizing the
need for prospective studies.